201 related articles for article (PubMed ID: 33154166)
1. 4-Phenylbutyric acid enhances the mineralization of osteogenesis imperfecta iPSC-derived osteoblasts.
Takeyari S; Kubota T; Ohata Y; Fujiwara M; Kitaoka T; Taga Y; Mizuno K; Ozono K
J Biol Chem; 2021; 296():100027. PubMed ID: 33154166
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of osteogenesis in iPSC-derived mesenchymal stem cells from osteogenesis imperfecta patients by endoplasmic reticulum stress inhibitor.
Duangchan T; Tawonsawatruk T; Angsanuntsukh C; Trachoo O; Hongeng S; Kitiyanant N; Supokawej A
Life Sci; 2021 Aug; 278():119628. PubMed ID: 34015290
[TBL] [Abstract][Full Text] [Related]
3. Makings of a brittle bone: Unexpected lessons from a low protein diet study of a mouse OI model.
Mertz EL; Makareeva E; Mirigian LS; Koon KY; Perosky JE; Kozloff KM; Leikin S
Matrix Biol; 2016; 52-54():29-42. PubMed ID: 27039252
[TBL] [Abstract][Full Text] [Related]
4. 4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion.
Besio R; Iula G; Garibaldi N; Cipolla L; Sabbioneda S; Biggiogera M; Marini JC; Rossi A; Forlino A
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1642-1652. PubMed ID: 29432813
[TBL] [Abstract][Full Text] [Related]
5. Targeting cellular stress in vitro improves osteoblast homeostasis, matrix collagen content and mineralization in two murine models of osteogenesis imperfecta.
Garibaldi N; Contento BM; Babini G; Morini J; Siciliani S; Biggiogera M; Raspanti M; Marini JC; Rossi A; Forlino A; Besio R
Matrix Biol; 2021 Apr; 98():1-20. PubMed ID: 33798677
[TBL] [Abstract][Full Text] [Related]
6. The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta.
Gioia R; Tonelli F; Ceppi I; Biggiogera M; Leikin S; Fisher S; Tenedini E; Yorgan TA; Schinke T; Tian K; Schwartz JM; Forte F; Wagener R; Villani S; Rossi A; Forlino A
Hum Mol Genet; 2017 Aug; 26(15):2897-2911. PubMed ID: 28475764
[TBL] [Abstract][Full Text] [Related]
7. Type V OI primary osteoblasts display increased mineralization despite decreased COL1A1 expression.
Reich A; Bae AS; Barnes AM; Cabral WA; Hinek A; Stimec J; Hill SC; Chitayat D; Marini JC
J Clin Endocrinol Metab; 2015 Feb; 100(2):E325-32. PubMed ID: 25387264
[TBL] [Abstract][Full Text] [Related]
8. Osteoblast Malfunction Caused by Cell Stress Response to Procollagen Misfolding in α2(I)-G610C Mouse Model of Osteogenesis Imperfecta.
Mirigian LS; Makareeva E; Mertz EL; Omari S; Roberts-Pilgrim AM; Oestreich AK; Phillips CL; Leikin S
J Bone Miner Res; 2016 Aug; 31(8):1608-1616. PubMed ID: 26925839
[TBL] [Abstract][Full Text] [Related]
9. Effect of rapamycin on bone mass and strength in the α2(I)-G610C mouse model of osteogenesis imperfecta.
Bateman JF; Sampurno L; Maurizi A; Lamandé SR; Sims NA; Cheng TL; Schindeler A; Little DG
J Cell Mol Med; 2019 Mar; 23(3):1735-1745. PubMed ID: 30597759
[TBL] [Abstract][Full Text] [Related]
10. Cell differentiation and matrix organization are differentially affected during bone formation in osteogenesis imperfecta zebrafish models with different genetic defects impacting collagen type I structure.
Daponte V; Tonelli F; Masiero C; Syx D; Exbrayat-Héritier C; Biggiogera M; Willaert A; Rossi A; Coucke PJ; Ruggiero F; Forlino A
Matrix Biol; 2023 Aug; 121():105-126. PubMed ID: 37336269
[TBL] [Abstract][Full Text] [Related]
11. Molecular Consequences of the SERPINH1/HSP47 Mutation in the Dachshund Natural Model of Osteogenesis Imperfecta.
Lindert U; Weis MA; Rai J; Seeliger F; Hausser I; Leeb T; Eyre D; Rohrbach M; Giunta C
J Biol Chem; 2015 Jul; 290(29):17679-17689. PubMed ID: 26004778
[TBL] [Abstract][Full Text] [Related]
12. Interaction between KDELR2 and HSP47 as a Key Determinant in Osteogenesis Imperfecta Caused by Bi-allelic Variants in KDELR2.
van Dijk FS; Semler O; Etich J; Köhler A; Jimenez-Estrada JA; Bravenboer N; Claeys L; Riesebos E; Gegic S; Piersma SR; Jimenez CR; Waisfisz Q; Flores CL; Nevado J; Harsevoort AJ; Janus GJM; Franken AAM; van der Sar AM; Meijers-Heijboer H; Heath KE; Lapunzina P; Nikkels PGJ; Santen GWE; Nüchel J; Plomann M; Wagener R; Rehberg M; Hoyer-Kuhn H; Eekhoff EMW; Pals G; Mörgelin M; Newstead S; Wilson BT; Ruiz-Perez VL; Maugeri A; Netzer C; Zaucke F; Micha D
Am J Hum Genet; 2020 Nov; 107(5):989-999. PubMed ID: 33053334
[TBL] [Abstract][Full Text] [Related]
13. Cell proliferation of human fibroblasts and osteoblasts in osteogenesis imperfecta: influence of age.
Fedarko NS; D'Avis P; Frazier CR; Burrill MJ; Fergusson V; Tayback M; Sponseller PD; Shapiro JR
J Bone Miner Res; 1995 Nov; 10(11):1705-12. PubMed ID: 8592947
[TBL] [Abstract][Full Text] [Related]
14. Multiexon deletions in the type I collagen COL1A2 gene in osteogenesis imperfecta type IB. Molecules containing the shortened alpha2(I) chains show differential incorporation into the bone and skin extracellular matrix.
Mundlos S; Chan D; Weng YM; Sillence DO; Cole WG; Bateman JF
J Biol Chem; 1996 Aug; 271(35):21068-74. PubMed ID: 8702873
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies of osteoblast and fibroblast type I collagen in a patient with osteogenesis imperfecta type IV.
Galicka A; Wolczynski S; Gindzienski A
J Pathol; 2002 Feb; 196(2):235-7. PubMed ID: 11793376
[TBL] [Abstract][Full Text] [Related]
16. Cellular stress due to impairment of collagen prolyl hydroxylation complex is rescued by the chaperone 4-phenylbutyrate.
Besio R; Garibaldi N; Leoni L; Cipolla L; Sabbioneda S; Biggiogera M; Mottes M; Aglan M; Otaify GA; Temtamy SA; Rossi A; Forlino A
Dis Model Mech; 2019 Jun; 12(6):. PubMed ID: 31171565
[TBL] [Abstract][Full Text] [Related]
17. Abnormal type I collagen post-translational modification and crosslinking in a cyclophilin B KO mouse model of recessive osteogenesis imperfecta.
Cabral WA; Perdivara I; Weis M; Terajima M; Blissett AR; Chang W; Perosky JE; Makareeva EN; Mertz EL; Leikin S; Tomer KB; Kozloff KM; Eyre DR; Yamauchi M; Marini JC
PLoS Genet; 2014 Jun; 10(6):e1004465. PubMed ID: 24968150
[TBL] [Abstract][Full Text] [Related]
18. A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor.
Farber CR; Reich A; Barnes AM; Becerra P; Rauch F; Cabral WA; Bae A; Quinlan A; Glorieux FH; Clemens TL; Marini JC
J Bone Miner Res; 2014 Jun; 29(6):1402-11. PubMed ID: 24519609
[TBL] [Abstract][Full Text] [Related]
19. COL1A1 C-propeptide mutations cause ER mislocalization of procollagen and impair C-terminal procollagen processing.
Barnes AM; Ashok A; Makareeva EN; Brusel M; Cabral WA; Weis M; Moali C; Bettler E; Eyre DR; Cassella JP; Leikin S; Hulmes DJS; Kessler E; Marini JC
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2210-2223. PubMed ID: 31055083
[TBL] [Abstract][Full Text] [Related]
20. Collagen transport and related pathways in Osteogenesis Imperfecta.
Claeys L; Storoni S; Eekhoff M; Elting M; Wisse L; Pals G; Bravenboer N; Maugeri A; Micha D
Hum Genet; 2021 Aug; 140(8):1121-1141. PubMed ID: 34169326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
